Insight Lifetech

Insight Lifetech (北芯生命, 688712.SH) is a Chinese innovative medical device company focused on precision cardiovascular intervention — products like IVUS catheters and wireless pressure microcatheters, both of which received NMPA Class III approvals in 2025 . Founded and led by Chairman & CEO Song Liang, the company listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026, pricing at CNY17.52 per share and opening at CNY50.31 for a market capitalization of CNY20.98 billion . Qiming Venture Partners was a major backer, leading the C round in 2020, continuing into the D round, and holding over 6% pre-IPO . In Song's own words at the listing, the company set out to fill a gap in China's highest-barrier device segment — high-performance precision cardiovascular interventional devices — while Qiming partner Oscar Zhang framed the IPO as validation of China's rising global competitiveness in medtech innovation .